MedTrace Logo

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

NCT03322995 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2026-01-08

No results posted yet for this study

Summary

This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.

Conditions

Interventions

DRUG

First-line Chemotherapy

The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.

DRUG

Second-line Chemotherapy

Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.

RADIATION

Chemoradiation

50.4 Gy in 28 fractions.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Kathleen Christians, MD · Professor

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-21
Primary Completion
2027-06-01
Completion
2032-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03322995 on ClinicalTrials.gov